Triumvira Immunologics

Triumvira Immunologics is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson of McMaster University in Canada and Bloom Burton & Co. The company aims to develop novel T-cell therapies that are safer and more effective than current cell therapy cancer treatments, including CAR-T and TCR-T. Our proprietary TAC technology leverages a new mechanism of action (MoA) that has the potential to enhance immune responses in millions of patients with difficult-to-treat tumors.